DSG-PEG-2000 Micellar Amphotericin B Formulation for Plasma Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Amphotericin B derivatives suffer from poor plasma compatibility and solution stability, limiting their effectiveness in treating invasive fungal infections due to toxicity and resistance issues.
Innovation Solution
A micellar formulation of Amphotericin B derivatives stabilized by a lipid polymer excipient, such as DSG-PEG-2000, enhances solution stability and plasma compatibility, maintaining potency and extending half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Amphotericin B derivatives are used to treat invasive fungal infections, then fungicidal activity is improved, but plasma compatibility and solution stability deteriorate
Solution Approach 1:
The patent uses a micellar formulation system as an intermediary carrier to deliver Amphotericin B derivatives. The micelles encapsulate the hydrophobic AmB derivative in their core, providing a hydrophilic exterior that ensures plasma compatibility and solution stability while maintaining fungicidal activity through controlled release of the active compound.
Solution Approach 2:
The invention creates a composite formulation combining Amphotericin B derivative with a micellar structure composed of amphiphilic block copolymers. This composite system integrates the antifungal properties of AmB with the stabilizing and solubilizing characteristics of the micellar carrier, resolving the contradiction between efficacy and stability.
2Reliability
If Amphotericin B derivatives are used to treat invasive fungal infections, then fungicidal activity is improved, but plasma compatibility deteriorates
Solution Approach 1:
The micellar formulation acts as a protective intermediary between the Amphotericin B derivative and the plasma environment. The micelle's hydrophilic shell shields the hydrophobic and potentially toxic AmB core from direct interaction with plasma components, thereby improving plasma compatibility while preserving fungicidal activity.
Solution Approach 2:
The micellar structure provides a flexible, dynamic shell that encapsulates the AmB derivative. This shell is composed of amphiphilic block copolymers that form a stable yet adaptable protective layer, enabling the formulation to withstand plasma conditions while maintaining the integrity and activity of the enclosed antifungal agent.
3Object-affected harmful factors
If dose-limiting toxicities are minimized through low-dose protocols, then mammalian toxicity is reduced, but treatment effectiveness deteriorates
Solution Approach 1:
The micellar formulation serves as a selective intermediary that enhances the therapeutic index by improving the selectivity of AmB delivery. The micelles facilitate targeted delivery to fungal cells while reducing non-specific interactions with mammalian cells, thereby enabling effective doses to be administered with reduced mammalian toxicity.
Solution Approach 2:
The invention changes the physical and chemical parameters of the Amphotericin B derivative by incorporating it into a micellar system. This transformation alters the solubility, stability, and cellular uptake characteristics of the drug, allowing for optimized dosing that achieves treatment effectiveness while minimizing mammalian toxicity.
Data Source
AI summary
Disclosed are compositions comprising a lipid polymer excipient and AmB or an AmB derivative. The lipid polymer excipient can form micelles when formulated with AmB or the AmB derivative and can solubilize and stabilize the drug. Also disclosed are methods of treating a fungal infection using the compositions.